Europe Lysosomal Disease Treatment Market Size, Share & Industry Trends Analysis Report By Disease Type, By Type of Therapy By End User, By Country and Growth Forecast, 2022

List of Tables

The Europe Lysosomal Disease Treatment Market would witness market growth of 5.7% CAGR during the forecast period (2022-2028).

Any lysosomal substrate stored causes an increase in the size and quantity of lysosomes in the lysosomal compartment. However, lysosomal compartment expansion alone does not result in mechanical damage that kills cells; other, more subtle pathways result in cell malfunction and ultimately cell death. For instance, various theories have been put out in recent years to explain why cholesterol deposition in the lipidoses causes disease. According to one theory, the endocytic system's raft membranes expand due to the storage of glycosphingolipids, which can be a primary or secondary characteristic of abnormal metabolism. This results in the inappropriate retention of cell surface receptors that are typically involved in plasma membrane raft signaling events.

According to a second idea, stored glycosphingolipids (GSLs) do not only accumulate in the lysosome but may also severely affect typical homeostatic activities in other cellular membranes. This idea has been biochemically demonstrated in type 1 Gaucher disease, where examination of fractionated cells revealed the accumulation of GlcCer in numerous organelle membranes. This is also in line with the finding from electron microscopy investigations that the late endosomal/lysosomal system (LE/Lys) is not the only location where membranes in cells that store lipids have electron densities.

In order to enhance stem cell therapies for the treatment of some of the most crippling diseases of the modern era, CIRM and the German ministry are establishing the groundwork for collaborative research projects. Researchers from California and Germany gathered in San Francisco around the end of last year to talk about a variety of topics of interest. The discussions at that meeting indicated that cooperation in several fields, including the research of immunology, could be particularly beneficial.

The Germany market dominated the Europe Lysosomal Disease Treatment Market by Country in 2021, thereby, achieving a market value of $711.6 Million by 2028. The UK market is experiencing a CAGR of 4.8% during (2022 - 2028). Additionally, The France market would witness a CAGR of 6.5% during (2022 - 2028).

Based on Disease Type, the market is segmented into Gaucher's Diseases, Fabry Diseases, Mucopolysaccharidosis, Pompe's Syndrome and Others. Based on Type of Therapy, the market is segmented into Enzyme Replacement Therapy, Substrate Reduction Therapy, Stem Cell Therapy and Others. Based on End User, the market is segmented into Hospitals, Clinics and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Eli Lilly And Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Sanofi S.A., Novartis AG, AstraZeneca PLC (Alexion Pharmaceuticals, Inc.), BioMarin Pharmaceutical Inc. and Sigilon Therapeutics, Inc.

Scope of the Study

Market Segments covered in the Report:

By Disease Type

Gaucher's Diseases
Fabry Diseases
Mucopolysaccharidosis
Pompe's Syndrome
Others

By Type of Therapy

Enzyme Replacement Therapy
Substrate Reduction Therapy
Stem Cell Therapy
Others

By End User

Hospitals
Clinics
Others

By Country

Germany
UK
France
Russia
Spain
Italy
Rest of Europe

Companies Profiled

Merck & Co., Inc.
Johnson & Johnson (Janssen Global Services, LLC)
Eli Lilly And Company
Pfizer, Inc.
Takeda Pharmaceutical Company Limited
Sanofi S.A.
Novartis AG
AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
BioMarin Pharmaceutical Inc.
Sigilon Therapeutics, Inc.

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 Europe Lysosomal Disease Treatment Market, by Disease Type
- 1.4.2 Europe Lysosomal Disease Treatment Market, by Type of Therapy
- 1.4.3 Europe Lysosomal Disease Treatment Market, by End User
- 1.4.4 Europe Lysosomal Disease Treatment Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview

2.1 Introduction
- 2.1.1 Overview
  - 2.1.1.1 Market composition & scenarios
2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints

Chapter 3. Europe Lysosomal Disease Treatment Market by Disease Type

3.1 Europe Gaucher's Diseases Market by Country
3.2 Europe Fabry Diseases Market by Country
3.3 Europe Mucopolysaccharidosis Market by Country
3.4 Europe Pompe's Syndrome Market by Country
3.5 Europe Others Market by Country

Chapter 4. Europe Lysosomal Disease Treatment Market by Type of Therapy

4.1 Europe Enzyme Replacement Therapy Market by Country
4.2 Europe Substrate Reduction Therapy Market by Country
4.3 Europe Stem Cell Therapy Market by Country
4.4 Europe Others Market by Country

Chapter 5. Europe Lysosomal Disease Treatment Market by End User

5.1 Europe Hospitals Market by Country
5.2 Europe Clinics Market by Country
5.3 Europe Others Market by Country

Chapter 6. Europe Lysosomal Disease Treatment Market by Country

6.1 Germany Lysosomal Disease Treatment Market
- 6.1.1 Germany Lysosomal Disease Treatment Market by Disease Type
- 6.1.2 Germany Lysosomal Disease Treatment Market by Type of Therapy
- 6.1.3 Germany Lysosomal Disease Treatment Market by End User
6.2 UK Lysosomal Disease Treatment Market
- 6.2.1 UK Lysosomal Disease Treatment Market by Disease Type
- 6.2.2 UK Lysosomal Disease Treatment Market by Type of Therapy
- 6.2.3 UK Lysosomal Disease Treatment Market by End User
6.3 France Lysosomal Disease Treatment Market
- 6.3.1 France Lysosomal Disease Treatment Market by Disease Type
- 6.3.2 France Lysosomal Disease Treatment Market by Type of Therapy
- 6.3.3 France Lysosomal Disease Treatment Market by End User
6.4 Russia Lysosomal Disease Treatment Market
- 6.4.1 Russia Lysosomal Disease Treatment Market by Disease Type
- 6.4.2 Russia Lysosomal Disease Treatment Market by Type of Therapy
- 6.4.3 Russia Lysosomal Disease Treatment Market by End User
6.5 Spain Lysosomal Disease Treatment Market
- 6.5.1 Spain Lysosomal Disease Treatment Market by Disease Type
- 6.5.2 Spain Lysosomal Disease Treatment Market by Type of Therapy
- 6.5.3 Spain Lysosomal Disease Treatment Market by End User
6.6 Italy Lysosomal Disease Treatment Market
- 6.6.1 Italy Lysosomal Disease Treatment Market by Disease Type
- 6.6.2 Italy Lysosomal Disease Treatment Market by Type of Therapy
- 6.6.3 Italy Lysosomal Disease Treatment Market by End User
6.7 Rest of Europe Lysosomal Disease Treatment Market
- 6.7.1 Rest of Europe Lysosomal Disease Treatment Market by Disease Type
- 6.7.2 Rest of Europe Lysosomal Disease Treatment Market by Type of Therapy
- 6.7.3 Rest of Europe Lysosomal Disease Treatment Market by End User

Chapter 7. Company Profiles

7.1 Merck & Co., Inc.
- 7.1.1 Company Overview
- 7.1.2 Financial Analysis
- 7.1.3 Segmental and Regional Analysis
- 7.1.4 Research & Development Expenses
7.2 Johnson & Johnson (Janssen Global Services, LLC)
- 7.2.1 Company Overview
- 7.2.2 Financial Analysis
- 7.2.3 Segmental &Regional Analysis
- 7.2.4 Research & Development Expenses
7.3 Eli Lilly And Company
- 7.3.1 Company Overview
- 7.3.2 Financial Analysis
- 7.3.3 Regional Analysis
- 7.3.4 Research & Development Expenses
- 7.3.5 Recent strategies and developments:
  - 7.3.5.1 Acquisition and Mergers:
7.4 Pfizer, Inc.
- 7.4.1 Company Overview
- 7.4.2 Financial Analysis
- 7.4.3 Regional & Segmental Analysis
- 7.4.4 Research & Development Expense
- 7.4.5 Recent strategies and developments:
  - 7.4.5.1 Partnerships, Collaborations, and Agreements:
7.5 Takeda Pharmaceutical Company Limited
- 7.5.1 Company Overview
- 7.5.2 Financial Analysis
- 7.5.3 Regional Analysis
- 7.5.4 Research & Development Expense
7.6 Sanofi S.A.
- 7.6.1 Company Overview
- 7.6.2 Financial Analysis
- 7.6.3 Segmental and Regional Analysis
- 7.6.4 Research & Development Expense
- 7.6.5 Recent strategies and developments:
  - 7.6.5.1 Approvals and Trials:
7.7 Novartis AG
- 7.7.1 Company Overview
- 7.7.2 Financial Analysis
- 7.7.3 Segmental and Regional Analysis
- 7.7.4 Research & Development Expense
7.8 AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
- 7.8.1 Company Overview
- 7.8.2 Financial Analysis
- 7.8.3 Regional Analysis
- 7.8.4 Research & Development Expenses
7.9 BioMarin Pharmaceutical Inc.
- 7.9.1 Company Overview
- 7.9.2 Financial Analysis
- 7.9.3 Regional Analysis
- 7.9.4 Research & Development Expenses
- 7.9.5 Recent strategies and developments:
  - 7.9.5.1 Approvals and Trials:
7.10. Sigilon Therapeutics, Inc.
- 7.10.1 Company Overview
- 7.10.2 Financial Analysis
- 7.10.3 Research & Development Expenses

LIST OF TABLES

TABLE 1 Europe Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 2 Europe Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 3 Europe Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 4 Europe Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 5 Europe Gaucher's Diseases Market by Country, 2018 - 2021, USD Million
TABLE 6 Europe Gaucher's Diseases Market by Country, 2022 - 2028, USD Million
TABLE 7 Europe Fabry Diseases Market by Country, 2018 - 2021, USD Million
TABLE 8 Europe Fabry Diseases Market by Country, 2022 - 2028, USD Million
TABLE 9 Europe Mucopolysaccharidosis Market by Country, 2018 - 2021, USD Million
TABLE 10 Europe Mucopolysaccharidosis Market by Country, 2022 - 2028, USD Million
TABLE 11 Europe Pompe's Syndrome Market by Country, 2018 - 2021, USD Million
TABLE 12 Europe Pompe's Syndrome Market by Country, 2022 - 2028, USD Million
TABLE 13 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 14 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 15 Europe Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 16 Europe Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 17 Europe Enzyme Replacement Therapy Market by Country, 2018 - 2021, USD Million
TABLE 18 Europe Enzyme Replacement Therapy Market by Country, 2022 - 2028, USD Million
TABLE 19 Europe Substrate Reduction Therapy Market by Country, 2018 - 2021, USD Million
TABLE 20 Europe Substrate Reduction Therapy Market by Country, 2022 - 2028, USD Million
TABLE 21 Europe Stem Cell Therapy Market by Country, 2018 - 2021, USD Million
TABLE 22 Europe Stem Cell Therapy Market by Country, 2022 - 2028, USD Million
TABLE 23 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 24 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 25 Europe Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 26 Europe Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 27 Europe Hospitals Market by Country, 2018 - 2021, USD Million
TABLE 28 Europe Hospitals Market by Country, 2022 - 2028, USD Million
TABLE 29 Europe Clinics Market by Country, 2018 - 2021, USD Million
TABLE 30 Europe Clinics Market by Country, 2022 - 2028, USD Million
TABLE 31 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 32 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 33 Europe Lysosomal Disease Treatment Market by Country, 2018 - 2021, USD Million
TABLE 34 Europe Lysosomal Disease Treatment Market by Country, 2022 - 2028, USD Million
TABLE 35 Germany Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 36 Germany Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 37 Germany Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 38 Germany Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 39 Germany Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 40 Germany Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 41 Germany Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 42 Germany Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 43 UK Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 44 UK Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 45 UK Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 46 UK Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 47 UK Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 48 UK Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 49 UK Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 50 UK Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 51 France Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 52 France Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 53 France Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 54 France Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 55 France Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 56 France Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 57 France Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 58 France Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 59 Russia Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 60 Russia Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 61 Russia Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 62 Russia Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 63 Russia Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 64 Russia Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 65 Russia Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 66 Russia Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 67 Spain Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 68 Spain Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 69 Spain Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 70 Spain Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 71 Spain Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 72 Spain Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 73 Spain Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 74 Spain Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 75 Italy Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 76 Italy Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 77 Italy Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 78 Italy Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 79 Italy Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 80 Italy Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 81 Italy Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 82 Italy Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 83 Rest of Europe Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 84 Rest of Europe Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 85 Rest of Europe Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 86 Rest of Europe Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 87 Rest of Europe Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 88 Rest of Europe Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 89 Rest of Europe Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 90 Rest of Europe Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 91 KEY INFORMATION - MERCK & CO., INC.
TABLE 92 Key information -Johnson & Johnson
TABLE 93 Key Information - Eli Lilly And Company
TABLE 94 Key Information - Pfizer, Inc.
TABLE 95 Key Information - Takeda Pharmaceutical Company Limited
TABLE 96 Key Information - Sanofi S.A.
TABLE 97 Key Information - Novartis AG
TABLE 98 KEY INFORMATION - ASTRAZENECA PLC
TABLE 99 Key Information - BioMarin Pharmaceutical Inc.
TABLE 100 Key Information - Sigilon Therapeutics, Inc.

List of Figures

FIG 1 Methodology for the research

Europe Lysosomal Disease Treatment Market Size, Share & Industry Trends Analysis Report By Disease Type, By Type of Therapy By End User, By Country and Growth Forecast, 2022 - 2028

Description

Table of Contents